The stock of Aligos Therapeutics Inc (ALGS) has seen a 9.80% increase in the past week, with a 31.76% gain in the past month, and a 3.43% flourish in the past quarter. The volatility ratio for the week is 8.53%, and the volatility levels for the past 30 days are at 11.38% for ALGS. The simple moving average for the past 20 days is 4.52% for ALGS’s stock, with a -48.70% simple moving average for the past 200 days.
Is It Worth Investing in Aligos Therapeutics Inc (NASDAQ: ALGS) Right Now?
ALGS has 36-month beta value of 2.77. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for ALGS is 4.22M, and currently, short sellers hold a 12.85% ratio of that float. The average trading volume of ALGS on July 04, 2025 was 155.82K shares.
ALGS stock’s latest price update
Aligos Therapeutics Inc (NASDAQ: ALGS) has seen a rise in its stock price by 7.25% in relation to its previous close of $7.31. However, the company has experienced a 9.80% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-18 that SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately.
Analysts’ Opinion of ALGS
Many brokerage firms have already submitted their reports for ALGS stocks, with H.C. Wainwright repeating the rating for ALGS by listing it as a “Buy”. The predicted price for ALGS in the upcoming period, according to H.C. Wainwright is $75 based on the research report published on August 19, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALGS reach a price target of $3, previously predicting the price at $2. The rating they have provided for ALGS stocks is “Overweight” according to the report published on January 06th, 2023.
Piper Sandler gave a rating of “Neutral” to ALGS, setting the target price at $4 in the report published on March 23rd of the previous year.
ALGS Trading at 24.35% from the 50-Day Moving Average
After a stumble in the market that brought ALGS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.25% of loss for the given period.
Volatility was left at 11.38%, however, over the last 30 days, the volatility rate increased by 8.53%, as shares surge +24.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +52.53% upper at present.
During the last 5 trading sessions, ALGS rose by +9.80%, which changed the moving average for the period of 200-days by -47.03% in comparison to the 20-day moving average, which settled at $7.50. In addition, Aligos Therapeutics Inc saw -15.01% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Aligos Therapeutics Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for ALGS
Current profitability levels for the company are sitting at:
- -26.41% for the present operating margin
- 0.61% for the gross margin
The net margin for Aligos Therapeutics Inc stands at -16.29%. The total capital return value is set at -0.66%. Equity return is now at value -60.44%, with -38.23% for asset returns.
Based on Aligos Therapeutics Inc (ALGS), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -10.02.
Currently, EBITDA for the company is -89.15 million with net debt to EBITDA at 0.78. When we switch over and look at the enterprise to sales, we see a ratio of -5.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.56.
Conclusion
To put it simply, Aligos Therapeutics Inc (ALGS) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
